Nova Therapeutics confirms FDA approval of VNT-101's IND application, a new direct-acting antivirus targeting Influenza A virus

Nova Therapeutics, Inc., a firm committed to bio-technology, specialising in creating treatments for Influenza A nucleoprotein inhibitor, has reported the U.S. FDA's go-ahead for its IND application for its influenza A nucleoprotein suppressant, VNT-101.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

"We are excited to progress with the clinical examination of VNT-101," mentioned Don Ganem MD, Via Nova Therapeutics' Co-Founder and Chief Executive Officer. "This development represents a major leap towards generating an innovative flu antiviral medication embodying a unique mode of action, marking a significant achievement for Via Nova Therapeutics as our first formulation progresses into the clinical stages."

VNT-101 is a groundbreaking investigational tiny molecule under development for the purpose of treating seasonal influenza A virus. It aims at a unique target, the influenza A nucleoprotein. Laboratory tests show VNT-101 effective against not just the seasonal influenza A but also high pathogenic avian influenza (HPAI) H5N1 and H7N9 strains. Due to its unique mode of action, VNT-101 has also shown efficacy against influenza A strains possessing resistance mutations to existing flu treatments in lab tests.

Driven by the goal to uncover and develop secure and effective novel therapy for viral illnesses where current remedies fall short, Via Nova was formed in August of 2021. They secured licensing of antiviral programs from Novartis which focus on influenza A virus, human rhinovirus, BK polyomavirus, and adenovirus. The programs address acute viral respiratory and eye infections, along with infections affecting immune-compromised patients.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

According to the data provided by the Synapse Database, As of September 29, 2023, there are 1 investigational drugs for the influenza virus nucleoprotein, including 1 indications,1 R&D institutions involved, and as many as 270 patents.

VNT-101 is designed to act on the nucleoprotein of the influenza virus. The main purpose of this medication is to manage Influenza A virus infection and it is classified under the medical fields of Infectious and Respiratory Diseases. Given the approval of its Investigational New Drug (IND) status, VNT-101 is already in its progressive development phases and represents a promising potential therapy for those suffering from this easily transmissible respiratory disease.